Skip to main content
OpenTrials

Clinical trial condition

Metastatic Non-small Cell Lung Cancer

Explore clinical trials studying Metastatic Non-small Cell Lung Cancer. Study availability and eligibility vary by location and protocol.

37 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Non-small Cell Lung Cancer trial results

Active, Not Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center Mskcc New York, United States
  • Providence Portland Medical Center Portland, Oregon, United States
View all 61 locations
View Trial Details
Active, Not Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations
  • ArriVent Investigative Site Prescott, Arizona, United States
  • ArriVent Investigative Site Sacramento, California, United States
  • ArriVent Investigative Site Whittier, California, United States
  • ArriVent Investigative Site Celebration, Florida, United States
View all 42 locations
View Trial Details
Active, Not Recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • UCLA Hematology/Oncology - Santa Monica Los Angeles, California, United States
  • St. Charles Health System Denver, Colorado, United States
  • The Gastroenterology Group, P.C. Honolulu, Hawaii, United States
  • Cancer Center of Kansas Wichita, Kansas, United States
View all 106 locations
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

NCT06212752

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Fujita Health University ( Site 4406) Toyoake, Aichi-ken, Japan
  • Kurume University Hospital ( Site 4412) Kurume, Fukuoka, Japan
  • Gunma Prefectural Cancer Center ( Site 4416) Otashi, Gunma, Japan
  • National Hospital Organization Hokkaido Cancer Center ( Site 4415) Sapporo, Hokkaido, Japan
View all 18 locations
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023) Phoenix, Arizona, United States
  • Clermont Oncology Center ( Site 0018) Clermont, Florida, United States
  • Mid Florida Hematology and Oncology Center ( Site 0010) Orange City, Florida, United States
  • University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0022) Chicago, Illinois, United States
View all 110 locations
View Trial Details
Active, Not Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more
Locations
  • Arrivent Investigative Site Daphne, Alabama, United States
  • Arrivent Investigative Site Yuma, Arizona, United States
  • Arrivent Investigative Site Fayetteville, Arkansas, United States
  • Arrivent Investigative Site Beverly Hills, California, United States
View all 208 locations
View Trial Details

Related conditions